Recently, the First Affiliated Hospital of Shantou University School of Medicine was awarded the title of the first batch of "Ankylosing Spondylitis Standardized Diagnosis and Treatment Center Construction Standard Unit" awarded by the China Federation of Rheumatology and Immunology Medical Associations, becoming the first medical institution in eastern Guangdong to receive this honor.
It is understood that in 2017, the rheumatology and immunology team of the hospital underwent strict assessment and was awarded the first batch of hospital member units by the China Rheumatology and Immunology Medical Federation Alliance. On November 22, 2020, sponsored by the National Clinical Research Center for Skin and Immune Diseases, the China Rheumatology Data Center, and the China Federation of Rheumatology Physicians, China's first "Standardized Diagnosis and Treatment Center for Ankylosing Spondylitis" project was officially launched, and the Rheumatology and Immunology Department of the hospital gave full play to the strong advantages of this specialty in the diagnosis and treatment of ankylosing spondylitis and successfully passed the assessment.
Hou Zhiduo, deputy chief physician of the Department of Rheumatology and Immunology, said that the department will take the opportunity of standardizing the construction of diagnosis and treatment centers to further improve the level of medical technology and provide patients with high-quality, standardized and cost-effective medical services; actively carry out rheumatism academic exchange activities in eastern Guangdong, give full play to the role of the chairman of the rheumatology professional committee of the Shantou Medical Association, and take the lead in promoting the academic development of rheumatism in eastern Guangdong; at the same time, strengthen medical cooperation with fraternal units in eastern Guangdong. Efforts should be made to promote the improvement of the overall level of prevention and treatment of wet immune diseases in Guangdong And Dongfeng to better meet the health needs of the people.
◎Promote the homogenization of the treatment of similar diseases
The reporter learned that ankylosing spondylitis is a chronic inflammatory disease that mainly affects the sacroiliac joint and spine, and can also affect the peripheral joints and internal organs, belonging to the category of rheumatism. The disease is often found in young adults, is relatively common in men, most of the disease is hidden, manifested as lumbar and hip pain, and is often misdiagnosed as lumbar muscle strain or lumbar disc disease. If not treated and treated in time, the disease can develop to an advanced stage due to joint destruction and bone fusion, resulting in spinal and joint deformities, impaired life functions and disability, which brings a heavy burden to the patient himself, his family and society.
As the deputy chairman unit of the Rheumatology Branch of the Guangdong Medical Association, the chairman unit of the Rheumatology Professional Committee of the Shantou Medical Association, and the key specialty of clinical medicine in Shantou, the Rheumatology and Immunology Department of the Hospital has been conducting early diagnosis and standardized treatment of ankylosing spondylitis since the 1980s, and the results have won the first prize of Shantou Science and Technology Progress Award, and successfully held two sessions of the National Collaborative Group Conference on Clinical and Epidemiological Research of Ankylosing Spondylitis.
The diagnosis scheme of ankylosing spondylitis proposed by the team is known as the "Shantou Standard" in the industry and is included in the book "Diagnostic Criteria for Internal Medicine Diseases", which has reached an international leading position in promoting the early diagnosis and treatment of ankylosing spondylitis. This standard was the first to introduce MRI and sacroiliac joint biopsy pathological examination at home and abroad as a supplement to the diagnosis of ankylosing spondylitis, and the International Collaborative Group on Spondyloarthritis has only included MRI into the diagnostic criteria in the past 10 years.
"The construction of standardized diagnosis and treatment centers has reached the standard, which shows that our diagnosis and treatment level and program of ankylosing spondylitis have been recognized nationwide." Hou Zhiduo said that the treatment of diseases today is no longer based on the personal experience of doctors, but the pursuit of unified standardized treatment. The hospital has become a standard unit for the construction of a standardized diagnosis and treatment center for ankylosing spondylitis, which can not only make a standardized assessment of the previous diagnosis and treatment of patients who come to the hospital, but also promote the experience of the hospital to the grass-roots hospitals in eastern Guangdong, become a regional benchmark, and promote the homogenization of the treatment of similar diseases.
◎Committed to the popularization and promotion of rheumatology
Hou Zhiduo said that in order to promote academic exchanges on rheumatism in eastern Guangdong, popularize and popularize the knowledge of rheumatism diagnosis and treatment, understand the new progress of rheumatism diagnosis and treatment, and further improve the level of clinical rheumatism diagnosis and treatment, the department also regularly carries out academic exchanges to share and discuss the diagnosis and treatment of special cases.
On November 13, 2021, sponsored by the Internal Physician Branch of the Guangdong Medical Doctor Association and the Rheumatology Committee of the Shantou Medical Association, and undertaken by the Department of Rheumatology and Immunology of the First Affiliated Hospital of Shantou University School of Medicine, the "National Successor Teaching Project "Study Class on Standardized Diagnosis and Treatment of Rheumatism and New Progress in Rheumatology" and the 2021 Academic Annual Meeting of the Rheumatology Committee of the Shantou Medical Association were successfully held in Shantou. This conference brought together the top experts and professors in the field of rheumatic immunology in China, facing clinical medical and scientific researchers in eastern Guangdong, providing an academic platform for exchanges between different disciplines, attracting medical personnel from Shantou, Jieyang, Chaozhou and other eastern Guangdong regions to actively participate in the meeting, and the academic atmosphere was strong.
Hou Zhiduo frankly said that there are many types of rheumatism, covering a wide range, causing great harm, and the Chaoshan population is large, but there are only a few registered rheumatologists. Due to the unknown etiology and pathological mechanism of some rheumatism, early diagnosis and standardized treatment are difficult, while some grass-roots physicians in eastern Guangdong have insufficient understanding of rheumatism, and the level of auxiliary examination of medical institutions is uneven, resulting in the widespread misdiagnosis, missed diagnosis and irregular treatment of rheumatism, which seriously affects the health and sustainable development of the people in eastern Guangdong. Therefore, he said that the continuing education of rheumatology in eastern Guangdong has a long way to go.
As the chairman of the Rheumatology Professional Committee of Shantou Medical Association, the Rheumatology and Immunology Department of the hospital is committed to promoting the popularization and promotion of early diagnosis and standardized treatment of rheumatism in medical and health units at all levels in Chaoshan and improving the quality of medical services. Hou Zhiduo revealed that at present, the department is also committed to promoting the establishment of the Rheumatology Alliance in eastern Guangdong, so as to promote the landing of two-way referral, so that patients with treatment difficulties can be referred from the primary hospital to the hospital, and patients with stable conditions can also return to the local follow-up.
◎Long-term research to improve the level of diagnosis and treatment technology
In the study of rheumatology, the Rheumatology and Immunology Department of the hospital has been unremittingly exploring. It is understood that this specialty is one of the earliest units in China to carry out genetic pharmacology research on ankylosing spondylitis treatment drugs, and has been committed to screening genetic indicators that effectively predict the drug treatment response of ankylosing spondylitis in China for many years, which has been applied and promoted in clinical practice, which is conducive to individualized precision treatment of different patients. In 2021, it will take the lead in opening a special outpatient clinic for ankylosing spondylitis in eastern Guangdong.
Hou Zhiduo introduced that in 2021, the Department of Rheumatology and Immunology of the First Affiliated Hospital of Shantou University School of Medicine and the Clinical Research Center jointly launched a "Clinical Characteristics and Prognosis Outcome Cohort Study of Axial Spondyloarthritis in China (COCAS Cohort)". The COCAS cohort is a single-center, two-way cohort study, which included more than 2,000 cases of axial spondyloarthritis, including ankylosing spondylitis, and was designed for follow-up observation for 30 years, with the purpose of studying the clinical characteristics and prognosis of axial spondyloarthritis in China, establishing a comprehensive index and model for effectively predicting disease outcome and treatment response, and is currently a cohort study with a large sample size and a long follow-up time in China.
The study of ankylosing spondylitis has lasted for 30 years, and some research results have been published. Hou Zhiduo further explained that on the one hand, the research focuses on observing the long-term prognosis changes of patients, so as to understand the development process of the disease. "At present, China lacks this kind of long-term observation, but mostly short-term observation, so it is difficult to know how many patients will eventually be disabled after treatment, how many people can maintain good life functioning, and how many people will make rapid progress in the short term." He said that through a wealth of research, a model can be built to predict the prognosis of patients, becoming a tool for assessing such diseases, rather than judging based on the experience of doctors alone. This is the first purpose of this study.
On the other hand, the study also compares different treatment regimens to see which regimen changes the patient's prognosis. Hou Zhiduo told reporters that rheumatism data show that the incidence of ankylosing spondylitis is about 0.26%, that is, there are more than 2,000 patients per 1 million people in Shantou. At present, there are more than 2,000 follow-up data established by the department. "These treatment options all need to go through a long process of big data observation for more than 10 years to be able to judge their effect on improving prognosis." Hou Zhiduo said that this is also the direction of the department's research.
[Reporter] Wang Hanqi
Click on the image to report the material with one click
【Author】 Wang Hanqi
【Source】 Southern Press Media Group South + client